Merck’s experimental COVID-19 antiviral pill appears effective, but may pose risks for pregnant women, including birth defects and toxicity to developing fetuses, according to the U.S. Food and Drug Administration. On Friday morning Merck announced updated results from its molnupiravir study that showed a smaller benefit than first thought: Among more than 1,400 adults in… read on > read on >











-300x200.jpeg)







